Latest Posts

Top panel seeks Liverpool law firm's expertise on international child abduction

International child abduction is a growing problem and a Liverpool law firm is now helping spearhead efforts to deal with the issue.

MSB Solicitors, which has offices in Liverpool city centre, Allerton and Wavertree, has been appointed to the International Child Abduction and Contact Panel by the Official Solicitors Office.

Firm joins elite list

The firm joins just 40 other firms in the UK on the panel – predominantly London-based – and is the only firm in the North West including Merseyside, Greater Manchester, Lancashire, North Wales and Cheshire.

International child abduction is the illegal removal of children from their home by a parent, acquaintance or family member to a foreign country. As international travel has become more common more people in the UK have formed relationships and had children with people in other countries.

However, when those relationships turn sour bitter custody disputes over the children can ensue and this can lead to cases where a child is abducted and taken to another country.

Call in the experts

MSB has built up considerable expert in such cases. Partner Emma Carey and family solicitor Emma Palmer are both Resolution-accredited specialists in this area.

Solicitor Eve McGowan is on the Law Society’s advanced specialist panel for child abduction, Kirsty Leather has completed a masters of law in international law and Wendy Eves has developed an reputation as a specialist, cross-border mediator.

Ms Carey said: “It really is a very difficult process to even be considered for appointment to the International Child Abduction and Contact Panel and I couldn’t be more proud of the efforts of the team at MSB.

“We have been involved in a number of incoming cases of international child abduction in recent years, which in itself is a feat, as often cases are submitted to solicitors firms already appointed to the panel.

Emma Carey, a partner in the family law department at MSB Solicitors in Liverpool

“I was first involved in an international child abduction case eight years ago and I have been resolution accredited for six years – this was an area of law I was interested to develop at MSB.

“I am lucky to be supported by a fantastic team who share my passion and their combined experience and commitment has been pivotal to us securing a place on the panel.”

Developing networks

MSB have spent a number of years taking steps to develop not only their experience, but their resources too – and to develop networks in London and across the country in order to carry out international child abduction work effectively.

Ms Carey added: “Often this type of work is very niche as it is incredibly complex. In many cases solicitors have to act quickly to put measures in place, whether that be to prevent children being removed from the country, or urgent action to establish the return of a child.

It is very emotive, time-consuming work and it has taken us a long time to ensure that we are confident in this area of law and that we have an effective support network.

“Legal aid is available for all child abduction matters, in some cases automatically, regardless of a client’s income or capital.

Go to Source

Leigh law firm offers free wills for charity

Christopher Hopkins, centre, and Anthony Higham, right, from Butcher and Barlow with a representative from Christian Aid

Christopher Hopkins, centre, and Anthony Higham, right, from Butcher and Barlow with a representative from Christian Aid

A LEIGH law company is set to provide people with free wills in return for a voluntary charitable donation.

Butcher and Barlow is one of a number of solicitor firms to have signed up to November’s Will Aid Month, which nationally raised £1 million last year.

James Lightfoot from Butcher and Barlow said: “We really enjoy taking part in Will Aid and are proud to be able to offer our solicitors’ time to write wills which have raised such fantastic sums for charity.

“Last year we raised more than £9,000 across three of our offices, which we are really proud of.

“We are really looking forward to Will Aid 2016 and will be working hard to raise more than last year.”

In Greater Manchester 23 solicitor firms signed up to Will Aid Month last year, raising just under £35,000 between them.

It relies on solicitors to pledge their time and support for the cause, providing a will writing service for free in return for a voluntary donation to charity from their client.

The cash raised is split between nine of the UK’s best-loved charities.

Peter de Vena Franks, campaign director for Will Aid, said: “Will Aid 2015 was a fantastic success but we are really hoping 2016 will surpass that.

“We want this year to be bigger and better than ever before.

“The sums raised by Greater Manchester solicitors were staggering in 2015, but we want even more solicitors to sign up to and donate their time, so we can help more and more people get their finances in order.

“Having a will is one of the most important yet easiest things to tick off the to-do list, and our charities benefit as a result.

Go to Source

Law favours slaughtering animals for food: SDPI

Madikeri, Aug 14, 2016, DHNS:

Social Democratic Party of India’s (SDPI) city unit secretary Mustafa on Saturday reminded BJP workers of an act that supports slaughtering of animals for food.

Addressing mediatresses here, Mustafa said there is a provision to kill animals for food according to an act introduced in 1966. It is also applicable to Kodagu and the BJP leaders are coming out with baseless statements without having a knowledge of the act, he charged.

Mustafa said according to statistics, India ranked top in the export of beef during 2014-15. Incidentally, a BJP legislator in Uttar Pradesh himself is a beef exporter. So also, four firms involved in same business in other parts of the country are owned by a particular community, he claimed.

He charged that the BJP, hiding all such facts, is creating chaos and confusion, besides indulging in attacking innocent dalits and minority community people.Mustafa suggested measures to check the cow slaughtering racket by legalising it with licence.

He also defended the speech of SDPI district unit president Ameen Mohsin on the issue at protest staged recently. He criticised that the BJP, which has no issues to fight the local body election, is engaged in a rift in the society.

MLA Apacchu Ranjan lacks concern towards development of the district. He is still unable to take up works on building private bus stand, Mustafa said.

Standing Committee president at Madikeri City Municipal Council Mansoor Ali said, “Food habits have the backing of Constitution of India.”

Go to Top

Go to Source

The World’s Most Dangerous Woman Launches All Sport Radio Show

The Most Dangerous Woman in the World

Renowned Fitness Trainer and Zumba Instructor

IFS Middleweight Muay Thai Kickboxing Champion

IFC and IFK Champion

IFS Middleweight and No. 1 Contender

Fredia “Cheetah” Gibbs – 3-Time Kickboxing World Champion To
Produce and Host “World of Sports with Cheetah”

Round for round, pound for pound, I will bring you interviews from the inner circle of the sports world.

— Cheetah

LOS ANGELES, CALIFORNIA, USA, August 12, 2016 /EINPresswire.com/ — World Champion and Professional Athlete Fredia “Cheetah” Gibbs and Producer Marie Lemelle, Platinum Star Public Relations have teamed up to produce a weekly one-hour radio show, “World of Sports with Cheetah.” The all-sports program broadcasts from the RMC Studios, 5047 W. Pico Blvd., Los Angeles, CA 90019 from 10:30 a.m. to 11:30 a.m. every Saturday. Audiences can call-in to speak to the host and/or guests at 323-965-1600 and watch/listen live at www.RMConair.com.

“Round for round, pound for pound, I will bring you interviews from the inner circle of the sports world,” said Cheetah who made history as the first African American woman to hold 3 titles in the kickboxing sport, which earned her the title “most dangerous woman in the world.”

The guests for August 13 are: Mary Casas Sandoval, a most sought after Latin zumba and dancehall fitness instructor in Northern America; Robert Renier IFS Middleweight Muay Thai Kickboxing Champion; Brandol Mendoza IFC and IFK Champion; Vincent Familari IFS middleweight and No. 1 contender; and Artist/Actor Shawn “Hazz” McDonald writer and performer of “Champion,” the theme song for the show.

“Cheetah is the epitome of team spirit and is the perfect choice as the host,” said Lemelle. “She has been in the winners’ circle and as an accomplished professional athlete has a high level of relationships in the sports world, real-life experiences, and a deep knowledge of kickboxing, boxing, track and field, and basketball.”

The show fills a much-needed niche that has been overlooked in mainstream media. To date, the growing line-up includes: David Huey- Trainer/ Fight Commentator; Master Shawn Shilati –Promoter; and Freddie Roach- Legendary Trainer; Jeff Meyers- Promoter; Don “The Dragon” Wilson, the only kick-boxer to win 11 world titles in 3 weight divisions; and Peter “Sugarfoot” Cunningham, an 8-Time undefeated, undisputed world champion kickboxer; and more. To stay informed, go to www.worldofsportswithcheetah.com or Facebook at www.facebook.com/fredia.c.gibbs.

As a former victim of bullying, Cheetah knows all too well, the importance of building self-esteem. “That’s why I learned mixed martial arts and threw more than 10,000 kicks per leg in one year,” said Cheetah, whose show endorses nonprofit organizations: BullyMeNotFoundation.com and ChampionWorldUSA.com. “Bullying is a global problem, and learning a form of self-defense like mixed martial arts will give you the confidence needed to stand up to bullies even if it is cyber-bullying –your mind is stronger than a verbal attack.”

For interviews with Cheetah, sponsorship and advertising opportunities, or to attend or be on the show, contact Producer Marie Lemelle at info@platinumstarpr.com.

About the Host – Fredia “Cheetah” Gibbs

Fredia Gibbs, nicknamed “Cheetah” and referred to as “The Most Dangerous Woman in the World,” is a sports icon and kickboxing legend. Gibbs, a 3-time World Champion in kickboxing, is a native of Chester, Philadelphia. Gibbs had an all-American career in high school basketball; then went on to play professionally in Europe. In 1994, Gibbs became a history-maker as the first African-American female to hold the world title in Muay Thai Kickboxing. Her next move took her to the world of professional boxing. She retired from the ring in 2002, with a record of 9-2-1.

Gibbs’ championship fight gear is displayed at the Mickey Vernon Sports Museum. Her championship belts are on display in a sports museum in Germany.

Today, she is a book author, celebrity trainer/transformer, philanthropist, motivational speaker, host tournaments, teaches seminars, and a weekly radio host. In 2016, Gibbs was honored and participated in the Orange County Heritage Parade and was nominated to attend the United State of Women summit hosted by the White House.

About Producer – Marie Y. Lemelle, MBA

More than 15 years ago, Marie Y. Lemelle’s entrepreneurial spirit led her to establish Platinum Star Public Relations, a certified MWBE and SBE, and an award-winning, global marketing and communications firm. Marie has taken her company global through her collaboration with the African Country Sierra Leone and to the next level as a one-stop shop to provide distribution, production and more. She is a certified TV/Film producer at Pasadena Media. Marie is associated with Red Cardinal Films, LLC in Las Vegas; Pendulum TV Network in Los Angeles; L.A. Praise TV Network in Inglewood, CA; One Shot Films; One Shot TV; CVTN; Mondo Entertainment; and Bonita Entertainment in Southern California.

A committed activist and civic leader, Marie is a member several social conscious associations. Marie is listed in the Who’s Who in Black Los Angeles. She writes a weekly column “Health Matters” published in the Los Angeles Wave Newspapers. Marie earned a Master’s in Business Administration from the University of La Verne and a Bachelor of Science degree from Excelsior College. www.platinumstarpr.wix.com/marielemelle

Marie Lemelle
Platinum Star PR
(213) 276-7827
email us here


Go to Source

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – KERX



NEW YORK, Aug. 12, 2016 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Keryx Biopharmaceuticals, Inc. (“Keryx” or the “Company”)












KERX, +0.47%










and certain of its officers.   The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-06233, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Keryx securities between February 25, 2016 and July 29, 2016 inclusive (the “Class Period”).  This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”). 

If you are a shareholder who purchased Keryx securities during the Class Period, you have until October 3, 2016 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. 


[Click here to join this class action]

Keryx is a biopharmaceutical company focused on marketing therapies for patients with renal disease. The Company’s product, Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, that received marketing approval from the U.S. Food and Drug Administration (“FDA”) in September 2014 for the control of serum phosphorus levels in patients with chronic kidney disease (“CKD”) on dialysis.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company was experiencing production-related difficulties in converting API to finished drug product; (ii) the foregoing difficulties were resulting in decreased production yields of finished drug product; (iii) consequently, the Company would exhaust its reserve of finished drug product; and (iv) as a result of the foregoing, Defendants’ statements about Keryx’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On August 1, 2016, pre-market, Keryx announced that it had determined that a supply interruption of Auryxia was going to occur due to a production-related issue in converting active pharmaceutical ingredient (“API”) to finished drug product at its contract manufacturer. The Company also disclosed that this issue has resulted in variable production yields of finished drug product, and that as a result, the Company had exhausted its reserve of finished drug product. Finally, the Company stated that it expects to restore adequate supply of Auryxia and make Auryxia available to patients during the fourth quarter of 2016.

On this news, Keryx’s stock price fell $2.64 per share, or 35.8%, to close at $4.72 per share on August 1, 2016, on unusually heavy trading volume.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert–pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-keryx-biopharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadline–kerx-300313055.html

SOURCE Pomerantz LLP

Copyright (C) 2016 PR Newswire. All rights reserved



















Go to Source

Shareholder Alert: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tokai Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – TKAI



NEW YORK, Aug. 12, 2016 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”)












TKAI, -0.87%










and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-06106, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Tokai securities between June 24, 2015 and July 25, 2016 inclusive (the “Class Period”).  This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”). 

If you are a shareholder who purchased Tokai securities during the Class Period, you have until September 30, 2016 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. 


[Click here to join this class action]

Tokai is a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate is galeterone, an oral small molecule that was, at all relevant times, in various clinical trials for the treatment of patients with metastatic castration-resistant prostate cancer.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) there were significant structural problems with the trial design for Tokai’s pivotal Phase 3 galeterone study, ARMOR3-SV; (ii) consequently, ARMOR3-SV was unlikely to succeed in meeting its primary endpoint; (iii) as a result, commercialization of galeterone was less likely and/or imminent than Tokai had led investors to believe; and (iv) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Tokai’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On November 2, 2015, Richard Pearson published an article on the investment website Seeking Alpha, entitled “What’s Wrong With Tokai Pharmaceuticals?” (the “Pearson Report”).  The Pearson Report described structural problems with the design of the Company’s ARMOR3-SV trial.

On this news, Tokai’s share price fell $0.07, or 0.63%, to close at $10.98 on November 2, 2015.

On July 26, 2016, Tokai announced plans “to discontinue the ARMOR3-SV clinical trial, our pivotal Phase 3 study” of galeterone. 

On this news, Tokai’s share price plummeted by $4.10, or nearly 79%, to close at $1.10 on July 26, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert–pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-tokai-pharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadline–tkai-300313061.html

SOURCE Pomerantz LLP

Copyright (C) 2016 PR Newswire. All rights reserved



















Go to Source

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Insmed Incorporated of Class Action Lawsuit and Upcoming Deadline – INSM

NEW YORK, NY / ACCESSWIRE / August 12, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM) and certain of its officers. The class action, filed in United States District Court District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Insmed securities between March 18, 2013 and June 8, 2016 inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased Insmed securities during the Class Period, you have until September 13, 2016 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

[Click here to join this class action]

Insmed, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapies for patients with serious lung diseases. The Company’s lead product candidate is Arikayce, or liposomal amikacin, for inhalation, a formulation of amikacin. Arikayce is in late-stage clinical development for treatment of nontuberculous mycobacteria (“NTM”) lung disease.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the data on which Insmed’s European marketing authorization application (“MAA”) for Arikayce relied was not likely to support approval by the European Medicines Agency (“EMA”) for the treatment of NTM lung disease; (ii) Arikayce’s approval by the EMA for the treatment of NTM lung disease and subsequent commercialization in Europe were thus less likely and/or imminent than Insmed had led investors to believe; and (iii) as a result of the foregoing, Insmed’s public statements were materially false and misleading at all relevant times.

On June 8, 2016, after the market closed, Insmed announced that it had withdrawn its MAA from the EMA for Arikayce for the treatment of NTM lung disease. The Company stated that “During the May 2016 Committee for Medicinal Products for Human Use (CHMP) meeting, the CHMP indicated that the phase 2 study did not provide a sufficient amount of evidence to support an approval. Insmed intends to resubmit its MAA when clinical data from its ongoing global phase 3 study are available.”

On this news, Insmed’s share price fell $0.99, or 8.24%, to close at $11.02 on June 9, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP


Go to Source

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tokai Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – TKAI

NEW YORK, Aug. 12, 2016 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”) (NASDAQ: TKAI) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-06106, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Tokai securities between June 24, 2015 and July 25, 2016 inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased Tokai securities during the Class Period, you have until September 30, 2016 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

[Click here to join this class action]

Tokai is a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate is galeterone, an oral small molecule that was, at all relevant times, in various clinical trials for the treatment of patients with metastatic castration-resistant prostate cancer.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) there were significant structural problems with the trial design for Tokai’s pivotal Phase 3 galeterone study, ARMOR3-SV; (ii) consequently, ARMOR3-SV was unlikely to succeed in meeting its primary endpoint; (iii) as a result, commercialization of galeterone was less likely and/or imminent than Tokai had led investors to believe; and (iv) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Tokai’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On November 2, 2015, Richard Pearson published an article on the investment website Seeking Alpha, entitled “What’s Wrong With Tokai Pharmaceuticals?” (the “Pearson Report”). The Pearson Report described structural problems with the design of the Company’s ARMOR3-SV trial.

On this news, Tokai’s share price fell $0.07, or 0.63%, to close at $10.98 on November 2, 2015.

On July 26, 2016, Tokai announced plans “to discontinue the ARMOR3-SV clinical trial, our pivotal Phase 3 study” of galeterone.

On this news, Tokai’s share price plummeted by $4.10, or nearly 79%, to close at $1.10 on July 26, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert–pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-tokai-pharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadline–tkai-300313061.html

SOURCE Pomerantz LLP


Go to Source